FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310079287> ?p ?o ?g. }

• W4310079287 endingPage "e144" @default.
• W4310079287 startingPage "e136" @default.
• W4310079287 abstract "BackgroundTyphoid conjugate vaccines are being introduced in low-income and middle-income countries to prevent typhoid illness in children. Vaccine effectiveness studies assess vaccine performance after introduction. The test-negative design is a commonly used method to estimate vaccine effectiveness that has not been applied to typhoid vaccines because of concerns over blood culture insensitivity. The overall aim of the study was to evaluate the appropriateness of using a test-negative design to assess typhoid Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TT) effectiveness using a gold standard randomised controlled trial database.MethodsUsing blood culture data from a randomised controlled trial of Vi-TT in Malawi, we simulated a test-negative design to derive vaccine effectiveness estimates using three different approaches and compared these to randomised trial efficacy results. In the randomised trial, 27 882 children aged 9 months to 12 years were randomly assigned (1:1) to receive a single dose of Vi-TT or meningococcal capsular group A conjugate vaccine between Feb 21 and Sept 27, 2018, and were followed up for blood culture-confirmed typhoid fever until Sept 30, 2021.FindingsFor all three test-negative design approaches, vaccine effectiveness estimates (test-negative design A, 80·3% [95% CI 66·2 to 88·5] vs test-negative design B, 80·5% [66·5 to 88·6] vs test-negative design C, 80·4% [66·9 to 88·4]) were almost identical to the randomised trial results (80·4% [95% CI 66·4 to 88·5]). Receipt of Vi-TT did not affect the risk of non-typhoid fever (vaccine efficacy against non-typhoid fever –0·4% [95% CI –4·9 to 3·9] vs –1% [–5·6 to 3·3] vs –2·5% [–6·4 to 1·3] for test-negative design A, test-negative design B, and test-negative design C, respectively).InterpretationThis study validates the test-negative design core assumption for typhoid vaccine effectiveness estimation and shows the accuracy and precision of the estimates compared with the randomised controlled trial. These results show that the test-negative design is suitable for assessing typhoid conjugate vaccine effectiveness in post-introduction studies using blood culture surveillance.FundingBill & Melinda Gates Foundation." @default.
• W4310079287 created "2022-11-30" @default.
• W4310079287 creator A5011158783 @default.
• W4310079287 creator A5015590965 @default.
• W4310079287 creator A5018146103 @default.
• W4310079287 creator A5033785570 @default.
• W4310079287 creator A5034013271 @default.
• W4310079287 creator A5037307507 @default.
• W4310079287 creator A5045561528 @default.
• W4310079287 creator A5051550648 @default.
• W4310079287 creator A5075206683 @default.
• W4310079287 creator A5081409930 @default.
• W4310079287 creator A5082847955 @default.
• W4310079287 creator A5089239945 @default.
• W4310079287 creator A5089631029 @default.
• W4310079287 date "2023-01-01" @default.
• W4310079287 modified "2023-10-14" @default.
• W4310079287 title "Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data" @default.
• W4310079287 cites W1534544164 @default.
• W4310079287 cites W2079151602 @default.
• W4310079287 cites W2102291836 @default.
• W4310079287 cites W2108178719 @default.
• W4310079287 cites W2150403485 @default.
• W4310079287 cites W2396494527 @default.
• W4310079287 cites W2507826825 @default.
• W4310079287 cites W2509529180 @default.
• W4310079287 cites W2551356525 @default.
• W4310079287 cites W2605758023 @default.
• W4310079287 cites W2897893390 @default.
• W4310079287 cites W2921283965 @default.
• W4310079287 cites W2968409833 @default.
• W4310079287 cites W2979697969 @default.
• W4310079287 cites W2993293153 @default.
• W4310079287 cites W3026389515 @default.
• W4310079287 cites W3128642443 @default.
• W4310079287 cites W3160138987 @default.
• W4310079287 cites W3184703747 @default.
• W4310079287 cites W3190947740 @default.
• W4310079287 cites W3196352038 @default.
• W4310079287 cites W3198593250 @default.
• W4310079287 cites W3200770050 @default.
• W4310079287 cites W3205215480 @default.
• W4310079287 cites W4210463927 @default.
• W4310079287 cites W4226553046 @default.
• W4310079287 cites W4245676516 @default.
• W4310079287 cites W4292377880 @default.
• W4310079287 doi "https://doi.org/10.1016/s2214-109x(22)00466-1" @default.
• W4310079287 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36442498" @default.
• W4310079287 hasPublicationYear "2023" @default.
• W4310079287 type Work @default.
• W4310079287 citedByCount "6" @default.
• W4310079287 countsByYear W43100792872023 @default.
• W4310079287 crossrefType "journal-article" @default.
• W4310079287 hasAuthorship W4310079287A5011158783 @default.
• W4310079287 hasAuthorship W4310079287A5015590965 @default.
• W4310079287 hasAuthorship W4310079287A5018146103 @default.
• W4310079287 hasAuthorship W4310079287A5033785570 @default.
• W4310079287 hasAuthorship W4310079287A5034013271 @default.
• W4310079287 hasAuthorship W4310079287A5037307507 @default.
• W4310079287 hasAuthorship W4310079287A5045561528 @default.
• W4310079287 hasAuthorship W4310079287A5051550648 @default.
• W4310079287 hasAuthorship W4310079287A5075206683 @default.
• W4310079287 hasAuthorship W4310079287A5081409930 @default.
• W4310079287 hasAuthorship W4310079287A5082847955 @default.
• W4310079287 hasAuthorship W4310079287A5089239945 @default.
• W4310079287 hasAuthorship W4310079287A5089631029 @default.
• W4310079287 hasBestOaLocation W43100792871 @default.
• W4310079287 hasConcept C126322002 @default.
• W4310079287 hasConcept C147483822 @default.
• W4310079287 hasConcept C159047783 @default.
• W4310079287 hasConcept C168563851 @default.
• W4310079287 hasConcept C203014093 @default.
• W4310079287 hasConcept C22070199 @default.
• W4310079287 hasConcept C2776714567 @default.
• W4310079287 hasConcept C2777351567 @default.
• W4310079287 hasConcept C2779583294 @default.
• W4310079287 hasConcept C2779841045 @default.
• W4310079287 hasConcept C2780454893 @default.
• W4310079287 hasConcept C2780801004 @default.
• W4310079287 hasConcept C40993552 @default.
• W4310079287 hasConcept C520601542 @default.
• W4310079287 hasConcept C71924100 @default.
• W4310079287 hasConceptScore W4310079287C126322002 @default.
• W4310079287 hasConceptScore W4310079287C147483822 @default.
• W4310079287 hasConceptScore W4310079287C159047783 @default.
• W4310079287 hasConceptScore W4310079287C168563851 @default.
• W4310079287 hasConceptScore W4310079287C203014093 @default.
• W4310079287 hasConceptScore W4310079287C22070199 @default.
• W4310079287 hasConceptScore W4310079287C2776714567 @default.
• W4310079287 hasConceptScore W4310079287C2777351567 @default.
• W4310079287 hasConceptScore W4310079287C2779583294 @default.
• W4310079287 hasConceptScore W4310079287C2779841045 @default.
• W4310079287 hasConceptScore W4310079287C2780454893 @default.
• W4310079287 hasConceptScore W4310079287C2780801004 @default.
• W4310079287 hasConceptScore W4310079287C40993552 @default.
• W4310079287 hasConceptScore W4310079287C520601542 @default.
• W4310079287 hasConceptScore W4310079287C71924100 @default.
• W4310079287 hasIssue "1" @default.

• next